No. 9,404,146 (the “146 Patent”), owned by Pacific Biosciences.
The 146 Patent, entitled “Compositions and methods for nucleic acid sequencing”, was issued in August of this year and covers novel methods for sequencing single nucleic acid molecules using linked double-stranded nucleic acid templates, providing improved sequencing accuracy.
Pacific Biosciences is asking the ITC to institute an investigation into the infringement of the 146 Patent by
“As a pioneer in the field of single molecule, long read sequencing, we have invested hundreds of millions of dollars in research and development across a broad array of disciplines, including nanofabrication, physics, organic chemistry, photonics, optics, molecular biology, engineering, signal processing, high performance computing, and bioinformatics,” said Dr.
About Pacific Biosciences
Biosciences of California
PacBio® sequencing systems, including consumables and software, provide a simple, fast, end-to-end workflow for SMRT Sequencing. More information is available at www.pacb.com.
All statements in this press release that are not historical are forward-looking statements, including, among other things, statements relating to actions or remedies sought from the ITC, enforcement of patent rights, and other future events. You should not place undue reliance on forward-looking statements because they involve known and unknown risks,
uncertainties, changes in circumstances and other factors that are, in some cases, beyond Pacific Biosciences’ control and could cause actual results to differ materially from the information expressed or implied by forward-looking statements made in this press release. Factors that could materially affect actual results can be found in Pacific Biosciences’ most recent filings with the Securities and Exchange Commission, including Pacific Biosciences’ most recent reports on Forms 8-K, 10-K and 10-Q, and include those listed under the caption “Risk Factors.”
Pacific Biosciences undertakes no obligation to revise or update information in this press release to reflect events or circumstances in the future, even if new information becomes available.
Contacts Media and Investors:
Trevin Rard650.521.8450 firstname.lastname@example.org
News Provided by Acquire Media